This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 220 Users Online

Postoperative Pain Management Market

Market Study on Postoperative Pain Management: North America to Remain Leading Regional Market

Postoperative Pain Management Market Segmented By Opioids, NSAIDS, Local Anaesthetics, and Acetaminophen Drugs in Injectable, Oral, Topical, Transdermal Route of Administration

Postoperative Pain Management Market Outlook (2022-2031)

The global market for postoperative pain management was valued at US$ 35.5 Bn in 2021. Market growth is predicted at 5% CAGR to reach a valuation of US$ 57.8 Bn by 2031.

Attribute Key Insights

Postoperative Pain Management Market Size (2021)

US$ 35.5 Bn

Projected Market Value (2031)

US$ 57.8 Bn

Global Market Growth Rate (2022-2031)

5% CAGR

Market Share of Top 5 Countries

67%

The opioids segment is the most dominating (61.9% share) owing to comparatively higher costs leading to more revenue and better pain relief. In 2021, postoperative pain management accounted for approximately 52.6% of the global pain management market.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Postoperative Pain Management Demand Analysis (2016-2021) Vs Market Outlook (2022-2031)

Sales of postoperative pain management drugs increased at a CAGR of 4.7% from 2016 to 2021.

Rising prevalence of chronic disease, growing number of surgical procedures, increasing demand for novel non-opioid analgesics in postoperative pain management therapy, and elevating awareness about palliative care are surging demand for postoperative pain treatment procedures.

Rising demand for pain management drugs is a driving factor for market growth. As per National Health statistics, 100 million surgeries takes place in the U.S. annually. Surging rate of surgeries across the globe is the main reason for the high consumption of pain management drugs. Similarly, increasing cancer therapy-associated pain incidence and growing pediatric and ageing population undergoing different types of surgeries are leading to the growth of the market.

Over the coming years, road accidents are expected to surge due to increasing number of vehicles. Also, many individuals do not follow road rules seriously. Rising cases of accidents on road, relative trauma injuries, and demand for pain management post surgeries are expected to drive postoperative pain management demand in future.

These incidents causes immense pain to the patient if not treated immediately and effectively. However, postoperative pain management is helpful to manage heavy pain and soreness. The availability of pain medications will be higher for such road accidents. The key players are increasing their production due to these factors which will ultimately lead to positive growth in the post-operative pain management market.

Increasing focus of key players on the development of abuse-deterrent opioid drugs and introduction of extended-release non-opioid drugs for post-surgery pain management are surging demand for painkiller drugs. Similarly, rising awareness regarding post-surgery pain control along with increased development and commercialization of non-narcotic drugs and non-abuse opioids is supplementing market growth.

Considering all these factors, Persistence Market Research expects the global postoperative pain management market to expand at a CAGR of 5% through 2031.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What is the Outlook for the Postoperative Pain Management Market?

Market Players Can Look to Asia and MEA for Growth Opportunities”

Opioids are commonly used for postoperative pain management in North America and Europe, but due to increased use of opioids for non-medical purposes, governing bodies are encouraging doctors to prescribe non-opioid drugs, which gives companies the opportunity to introduce novel non-opioid drugs.

In North America and Europe, clinicians can choose non-opioid medicine formulations with innovative drug delivery systems over opioid drugs for postoperative pain management. While opioid and non-opioid drugs with innovative drug delivery systems are not generally accessible for postoperative pain management in Asia and Africa.

Due to the lack of efficient postoperative pain management medications, a large section of the population in Asia and Africa stays untreated, thereby creating potential for postoperative pain management market players to grow in these regions.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Are There Any Restraints for Post-op Pain Relief Market Expansion?

“Concerns Regarding Overuse of Opioids to Negatively Impact Market Growth”

Growing concerns regarding the opioid epidemic and increasing cost burden of pain management on reimbursement providers are factors expected to hamper market expansion of pain management in postoperative patients to some extent.

Adverse side effects associated with excessive intake of NSAIDs and opioids and limited availability of postoperative pain management drugs are other factors hampering the market in Asia and Africa. For example, high consumption of morphine could result in severe damage to the respiratory system, which can even result in coma and death. Long-term use of morphine can result in its psychological and physical addiction, and could substantially dent the body’s immune posture.

Increase in drug abuse incidence and the addictive nature of opioids have declined the use of prescriptions for opioids in developed region. This has led to decrease in opioid consumption for pain management, which may further affect market growth.

postoperative-pain-management-market

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

What Makes the U.S. a Huge Market for Postoperative Pain Management?

“Strong Postoperative Pain Management Drug Pipeline in the U.S.”

The U.S. is estimated to account for 87.9% of the North America postoperative pain management market in 2022. Adoption of opioid management treatment is expected to reduce the growing prevalence of the opioid epidemic in North America, especially in the U.S. For instance, in 2017, 191 million opioid drugs were prescribed and dispensed to patients in the U.S.

Furthermore, presence of a strong drug pipeline with effective drugs coming up for approvals by the U.S. Food and Drug Administration is further expected to increase the use of postoperative pain management drugs in this region.

Which Country is a Lucrative Market for Pain Management in Postoperative Patients in Europe?

“Germany to Lead Opioid Dependence Treatment in Europe”

Germany is expected to account for 26.9% of the European postoperative pain management market in 2022.

High incidence and severity of postoperative pain, introduction of promising drugs, increase in the number of surgical procedures, and high rate of pain management procedures in developed countries such as Germany have driven market growth.

Increasing acceptance of Opioid Maintenance Treatment (OMT) for treating Opioid Dependence (OD) is a major factor propelling demand for postoperative pain management drugs across Germany.

What’s Fueling Demand for Postoperative Pain Management Medication in China?

“High Number of Surgeries Driving Demand in China”

The China postoperative pain management market is projected to expand at 6.6% CAGR due to increasing number of surgeries in the country.

Numerous pain management drugs manufacturers are undergoing distribution agreements, partnerships, and launching postoperative pain management medications in the Asia Pacific region, especially in China.

  • For instance, on May 1, 2018, Grunenthal signed a distribution and license agreement with Mundipharma; this agreement allowed Mundipharma to promote and distribute Grunenthal’s tramal (tramadol) in China.

Category-wise Insights

Which Drug Class Holds Maximum Sway in this Industry?

“Demand for Opioid Drugs to Continue Gaining Traction”

By drug class, the opioids segment is anticipated to hold a high share of 61.3% in 2022, expanding at 4% CAGR during the forecast period.

As per NIH, adults suffering from moderate to severe pain after surgery are mostly treated with opioids. Thus, use of opioids is increasing over the last decade. Based on research studies and ongoing trials, opioid drugs are known to be effective for postoperative pain treatment and have exhibited the ability to support patients in achieving their clinical goals.

Which Route of Administration is the Most Popular?

“Oral Postoperative Pain Management Procedures Highly Sought-after”

In terms of route of administration, oral postoperative pain management is projected to account for 37.8% of the total market share in 2022. The oral route of administration is a widely accepted and more convenient for patients, especially for the elder population, which leads to a higher market share in the postoperative pain management landscape.

Impact of COVID-19 Crisis

The market for postoperative pain management was hampered by unfavorable changes in regulations and guidelines during COVID-19. Cancer patients were at higher risk of COVID-19 infection than healthy persons, according to major regulatory bodies throughout the world (such as the CDC, WHO, MHRA, TGA, and EMA).

As a result, screening, diagnostic tests, and surgical treatments in hospitals and cancer centers were severely limited or postponed. The postoperative pain management market was disrupted as a result of this. Most hospitals gave more importance to COVID-19 treatment and care, and only emergency surgeries were taking place.

However, from the second half of 2021, the market has progressively grown owing to an increase in the number of infusion appointments and ablation operations, among other things, as a consequence of efforts to clear backlogs and new cases, as well as completely reopen healthcare services.

Competitive Landscape

Leading suppliers of postoperative pain management medicines are undertaking collaborations and acquisitions as the main strategy with different pharmaceutical companies for the development of novel product lines of drugs for pain management.

  • For example, in May 2020, Assertio Therapeutics, Inc. was acquired by Zyla Life Sciences. This created a growing commercial pharmaceutical company to increase its product portfolio in the neurology, inflammation, and pain products division.

Postoperative Pain Management Market Report Scope

Attribute Details

Forecast Period

2022-2031

Historical Data Available for

2016-2021

Market Analysis

US$ Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • BENELUX
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • Turkey
  • South Africa

Key Market Segments Covered

  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Allergan plc
  • Mylan N.V.
  • Pfizer Inc.
  • Purdue Pharma L.P
  • Janssen Pharmaceuticals, Inc.
  • Endo International plc.
  • Pacira Pharmaceuticals Inc.
  • Egalet Corporation
  • GlaxoSmithKline Plc.

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Postoperative Pain Management Industry Survey by Category

Postoperative Pain Management Market by Drug Class:

  • Opioids
  • NSAIDs
  • Local Anesthetic
  • Acetaminophen

Postoperative Pain Management Market by Route of Administration:

  • Injectable Postoperative Pain Management
  • Oral Postoperative Pain Management
  • Topical Postoperative Pain Management
  • Transdermal Postoperative Pain Management
  • Others

Postoperative Pain Management Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Clinics
  • Others

Postoperative Pain Management Market by Region:

  • North America Postoperative Pain Management Market
  • Latin America Postoperative Pain Management Market
  • Europe Postoperative Pain Management Market
  • East Asia Postoperative Pain Management Market
  • South Asia Postoperative Pain Management Market
  • Oceania Postoperative Pain Management Market
  • The Middle East and Africa (MEA) Postoperative Pain Management Market

- Companies Covered in This Report -

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Allergan plc
  • Mylan N.V
  • Pfizer Inc.
  • Purdue Pharma L.P
  • Janssen Pharmaceuticals, Inc.
  • Endo International plc
  • Pacira Pharmaceuticals Inc.
  • Egalet Corporation
  • GlaxoSmithKline Plc.

- Frequently Asked Questions -

The global post-op pain relief market is predicted to reach a valuation of US$ 57.58 Bn by 2032, up from US$ 35.5 Bn in 2021.

The global postoperative pain management market is projected to reflect a CAGR of 5% owing to rising prevalence of cancer, trauma, and accidental injuries, and increasing number of surgical procedures.

North America currently holds 46.4% of the global market share, with the U.S. being the leading contributor with a market value of around US$ 14.5 Bn in 2021.

The postoperative pain management market in India is likely to surge at a CAGR of 6.8% through 2032.

Increase in demand for opioid analgesics, investments in product development for new non-abuse opioids, and corporate tie-ups with distributors and industry specialists are key trends in this marketplace.

The Japan postoperative pain management market is set to exhibit healthy growth at 8% CAGR over the decade.

The U.S., China, Germany, France, and Canada are the top 5 countries driving market growth.

Leading postoperative pain management drug suppliers are Teva Pharmaceutical Industries Ltd.,   Novartis AG, Allergan plc, Mylan N.V., Pfizer Inc., Purdue Pharma L.P, Janssen Pharmaceuticals, Inc., Endo International plc, Pacira Pharmaceuticals Inc., Egalet Corporation, and GlaxoSmithKline Plc.

Google translate